Healthcare
Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain
PARIS, July 20, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that Sibnayal® (a prolonged-release combination of potassium citrate and potassium bicarbonate) is now reimbursed in Spain for the treatment of distal Renal Tubular Acidosis (dRTA).
About this update from Advicenne Sa
PARIS, July 20, 2026--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that Sibnayal® (a prolonged-release combination of potassium citrate and potassium bicarbonate) is now reimbursed in Spain for the treatment of distal Renal Tubular Acidosis (dRTA). The reimbursed prices of Sibnayal® in Spain are: - €409.84 including tax for Sibnayal® 24 mEq 847mg/1582 mg- €136.62 including tax for Sibnayal® 8 mEq 282 mg/527 mg Since its approval, Sibnayal® is available to Spanish patients through an early access program, which is ending with the official reimbursement. Sibnayal® is distributed locally by SPA Farma Iberica. Didier Laurens, Chief Executive Officer of Advicenne, stated: "We are delighted that our partner, SPA Farma Iberica, has succeeded in securing reimbursement in Spain. I would like to extend my sincere thanks to them for their ongoing commitment and the efforts they have made to provide Spanish patients with broader access to Sibnayal®. For their part, the Spanish health authorities have thus recognized the value of Sibnayal® in the management of a rare disease for which no other authorized treatment exists. This success marks another important milestone for our flagship treatment in Europe, with reimbursement in one of the continent's largest markets." * * * About Advicenne Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU, GB, KSA and UAE, and has been filed for a US NDA. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/. Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-lo...